HealthCor Management L.P. reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 33.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 622,997 shares of the company’s stock after selling 308,533 shares during the quarter. LivaNova makes up approximately 1.6% of HealthCor Management L.P.’s investment portfolio, making the stock its 25th largest position. HealthCor Management L.P. owned about 1.29% of LivaNova worth $49,790,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors also recently modified their holdings of the company. Vaughan Nelson Investment Management L.P. acquired a new position in shares of LivaNova in the 4th quarter valued at $55,467,000. Hermes Investment Management Ltd. acquired a new position in shares of LivaNova in the 4th quarter valued at $39,663,000. Dimensional Fund Advisors LP lifted its stake in shares of LivaNova by 42.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,317,901 shares of the company’s stock valued at $92,331,000 after purchasing an additional 395,672 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of LivaNova by 126.7% in the 3rd quarter. American Century Companies Inc. now owns 391,099 shares of the company’s stock valued at $27,400,000 after purchasing an additional 218,599 shares during the last quarter. Finally, NWQ Investment Management Company LLC lifted its stake in shares of LivaNova by 71.2% in the 3rd quarter. NWQ Investment Management Company LLC now owns 500,594 shares of the company’s stock valued at $35,072,000 after purchasing an additional 208,264 shares during the last quarter. Institutional investors own 85.52% of the company’s stock.
LivaNova PLC (LIVN) opened at $87.55 on Monday. LivaNova PLC has a 12 month low of $48.16 and a 12 month high of $92.31. The company has a current ratio of 2.14, a quick ratio of 1.79 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $4,228.33, a PE ratio of 24.80, a P/E/G ratio of 2.74 and a beta of 0.75.
Several equities analysts have recently commented on the company. BidaskClub lowered LivaNova from a “buy” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC reaffirmed a “buy” rating and issued a $104.00 price target (up previously from $97.00) on shares of LivaNova in a research note on Wednesday, February 28th. Canaccord Genuity increased their target price on LivaNova from $76.00 to $81.00 and gave the stock a “hold” rating in a research note on Tuesday, February 27th. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research lowered LivaNova from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. LivaNova has an average rating of “Hold” and an average target price of $81.43.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $83.32, for a total transaction of $83,320.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 3,000 shares of company stock worth $246,270. 0.28% of the stock is owned by corporate insiders.
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.